These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8447129)
1. [New, in Austria registered specialty drugs. Normoxin (moxonidine)]. Kögler H; Raneburger J Wien Klin Wochenschr; 1993; 105(3):94-6. PubMed ID: 8447129 [No Abstract] [Full Text] [Related]
2. [Moxonidine. A new centrally active antihypertensive drug]. Schrader J; Molderings GJ; Dominiak P Internist (Berl); 1992 Oct; 33(10):704-6. PubMed ID: 1428688 [No Abstract] [Full Text] [Related]
3. Effective antihypertensive therapy: blood pressure control with moxonidine. Prichard BN; Graham BR J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298 [TBL] [Abstract][Full Text] [Related]
4. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. Sharma AM; Wagner T; Marsalek P J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of moxonidine in mild to moderate hypertension. Jain S; Malhotra P; Kumari S; Varma S J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474 [TBL] [Abstract][Full Text] [Related]
6. Moxonidine for hypertension. Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. Prichard BN; Owens CW; Graham BR J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737 [TBL] [Abstract][Full Text] [Related]
8. Moxonidine well tolerated and effective in the treatment of viscerally obese, non-controlled hypertensive patients. Cardiovasc J S Afr; 2006; 17(4):209. PubMed ID: 17001427 [No Abstract] [Full Text] [Related]
9. Moxonidine: a new antiadrenergic antihypertensive agent. Prichard BN; Graham BR; Owens CW J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098 [TBL] [Abstract][Full Text] [Related]
11. [Administration of a new hypotensive agent 2-(2,6-dichlorphenylamino) imidazoline chlorhydrate in the treatment of essential arterial hypertension]. Borrello G Clin Ter; 1971 Apr; 57(1):9-29. PubMed ID: 5090286 [No Abstract] [Full Text] [Related]
12. [Evaluation of the antihypertensive drugs carvedilol, doxazosin and moxonidine]. Dominiak P Wien Med Wochenschr; 1995; 145(15-16):373-82. PubMed ID: 7502518 [TBL] [Abstract][Full Text] [Related]
14. [Behavior of hemodynamic values of patients with hypertension during dichlorphenylamino-imidazoline therapy]. Pozenel H Wien Klin Wochenschr; 1969 Mar; 81(11):187-92. PubMed ID: 4935483 [No Abstract] [Full Text] [Related]
15. Moxonidine: a review of safety and tolerability after seven years of clinical experience. Schachter M J Hypertens Suppl; 1999 Aug; 17(3):S37-9. PubMed ID: 10489097 [TBL] [Abstract][Full Text] [Related]
19. [Pathogenetic role of moxonidine in the treatment of hypertension in postmenopausal women]. Podzolkov VI; Bragina AE; Makolkin VI Kardiologiia; 2002; 42(11):32-5. PubMed ID: 12494033 [TBL] [Abstract][Full Text] [Related]
20. Properties of catapres, a new hypotensive drug: a preliminary report. Ng J; McGrgor DD; Taylor KM; Smirk H N Z Med J; 1967 Dec; 66(425):864-70. PubMed ID: 5236015 [No Abstract] [Full Text] [Related] [Next] [New Search]